Abstract | OBJECTIVE: DATA SOURCES: Data from more than 1800 outpatients with DSM-IV-defined GAD were analyzed from 3 short-term (8-week) studies and a longer (6-month) relapse prevention study. These studies were all randomized, double-blind, placebo-controlled trials of paroxetine. DATA SYNTHESIS: The results emphasize the benefit of paroxetine treatment in GAD, enabling a substantial proportion of patients to achieve clinical remission and preventing relapse. Long-term treatment with paroxetine also shows good tolerability with no evidence of weight gain. CONCLUSION: Given the high comorbidity of psychiatric depression and anxiety, the long-term efficacy and tolerability of paroxetine are important considerations when selecting a first-line therapy for patients with GAD.
|
Authors | Karl Rickels, Moira Rynn, Malini Iyengar, David Duff |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 67
Issue 1
Pg. 41-7
(Jan 2006)
ISSN: 0160-6689 [Print] United States |
PMID | 16426087
(Publication Type: Comparative Study, Journal Article, Meta-Analysis)
|
Chemical References |
- Placebos
- Serotonin Uptake Inhibitors
- Paroxetine
|
Topics |
- Adult
- Ambulatory Care
- Anxiety Disorders
(diagnosis, drug therapy, psychology)
- Diagnostic and Statistical Manual of Mental Disorders
- Female
- Headache
(chemically induced)
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Nausea
(chemically induced)
- Paroxetine
(adverse effects, therapeutic use)
- Placebos
- Psychiatric Status Rating Scales
- Randomized Controlled Trials as Topic
- Secondary Prevention
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
- Treatment Outcome
|